Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
Key Highlights
- ➤TTI-101 HCC topline data expected in early first quarter of 2027
- ➤Cash and equivalents $22.3 million; runway extends into third quarter of 2027
- ➤TTI-109 UC trial initiation planned for 2027, subject to funding and IND clearance
- ➤Q3 net loss $6.1 million versus $5.5 million year over year
- ➤Q3 R&D expenses $4.5 million, up from $3.6 million year over year
Expert Statements
Imran Alibhai, Chief Executive Officer of Tvardi Therapeutics
“We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps.”
HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the third quarter ended September 30, 2026, and provided a business update.
TTI-109 – Ulcerative Colitis (UC) * Advancing development plans for TTI-109 in UC. Building on positive Phase 1 healthy volunteer results reported in July and the subsequent selection of UC as its initial target indication, Tvardi is preparing to advance TTI-109 into clinical development in UC, subject to clearance of our Investigational New Drug (IND) application and additional funding. * The Phase 1 results confirmed the prodrug design, with TTI-109 delivering TTI-101-equivalent exposure with improved tolerability and, across the active dose range, demonstrated reductions in cellular and humoral immune populations known to correlate with UC disease severity, providing pharmacodynamic evidence of STAT3 target engagement.
Get started
Create a free account to read the full story.